Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Miyashita, N.
Right arrow Articles by Matsushima, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyashita, N.
Right arrow Articles by Matsushima, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 403-405
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae

Naoyuki Miyashita,*, Hiroshi Fukano, Yoshihito Niki and Toshiharu Matsushima

Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama 701-0192, Japan

The in vitro activity of telithromycin, a new ketolide, was compared with those of roxithromycin, azithromycin, clarithromycin and erythromycin A against 20 strains of Chlamydia pneumoniae. The MICs and minimal chlamydiacidal concentrations of telithromycin for the 20 C. pneumoniae strains both ranged between 0.031 and 0.25 mg/L. Telithromycin was twice as active as roxithromycin, azithromycin and erythromycin A, but less active than clarithromycin. These results appear to indicate that telithromycin is an effective antibiotic that should play some role in the treatment of respiratory tract infections caused by C. pneumoniae.

* Corresponding author. Tel: +81-86-462-1111; Fax: +81-86-463-6510; E-mail: nao{at}med.kawasaki-m.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku
Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
F. Blasi
Atypical pathogens and respiratory tract infections
Eur. Respir. J., July 1, 2004; 24(1): 171 - 182.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Miyashita, H. Fukano, K. Yoshida, Y. Niki, and T. Matsushima
In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae
J. Antimicrob. Chemother., September 1, 2003; 52(3): 497 - 499.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. R. Hammerschlag, T. Reznik, P. M. Roblin, J. Ramirez, J. Summersgill, and S. Bukofzer
Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae
J. Antimicrob. Chemother., April 1, 2003; 51(4): 1025 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
N. Miyashita, H. Fukano, K. Yoshida, Y. Niki, and T. Matsushima
Chlamydia pneumoniae infection in adult patients with persistent cough
J. Med. Microbiol., March 1, 2003; 52(3): 265 - 269.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.